US 12,274,705 B2
Composition comprising CYP4A-inhibiting compound as active ingredient for preventing or treating metabolic diseases
Gun Hwa Kim, Daejeon (KR); Min Ji Lee, Daejeon (KR); Koon Soon Kim, Daejeon (KR); Hyo Kyun Chung, Daejeon (KR); Ji Hoon Lee, Daejeon (KR); Se Jin Jung, Daejeon (KR); and Da Rong Kim, Daejeon (KR)
Assigned to Korea Basic Science Institute, Daejeon (KR)
Appl. No. 17/416,883
Filed by Korea Basic Science Institute, Daejeon (KR)
PCT Filed Dec. 19, 2019, PCT No. PCT/KR2019/018147
§ 371(c)(1), (2) Date Jun. 21, 2021,
PCT Pub. No. WO2020/130696, PCT Pub. Date Jun. 25, 2020.
Claims priority of application No. 10-2018-0167685 (KR), filed on Dec. 21, 2018.
Prior Publication US 2022/0218726 A1, Jul. 14, 2022
Int. Cl. A61K 31/496 (2006.01); A61K 31/635 (2006.01); A61P 1/16 (2006.01); A61P 3/10 (2006.01)
CPC A61K 31/635 (2013.01) 8 Claims
 
1. A method of treating a diabetes and fatty liver disease comprising administering to a subject a pharmaceutically effective amount of a pharmaceutical composition comprising the compound of Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient:

OG Complex Work Unit Chemistry
wherein R1, R2, R3, R4, R5 and R6 are each independently selected from the group consisting of hydrogen, halo, hydroxy, amino, carboxyl, cyano, nitro, alkyl, alkenyl, alkynyl and alkoxy.